Evidence map›Paper›PMID 24365657›Full record

ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2014

Developing novel blood-based biomarkers for Alzheimer's disease.

Heather M Snyder, Maria C Carrillo, Francine Grodstein, Kim Henriksen, Andreas Jeromin, Simon Lovestone, Michelle M Mielke, Sid O'Bryant, Manual Sarasa, Magnus Sjøgren and 9 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. "Advances in biomarker discovery and diagnostics for alzheimer's disease".Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Heather M SnyderMedical and Scientific Relations, Alzheimer's Association, Chicago, IL, USA. Electronic address: hsnyder@alz.org.
Maria C CarrilloMedical and Scientific Relations, Alzheimer's Association, Chicago, IL, USA.
Francine GrodsteinDepartment of Medicine, Brigham and Women's Hospital, Inc., Boston, MA, USA.
Kim HenriksenBiomarker and Research Division, Nordic Biosciences, Copenhagen, Denmark.
Andreas JerominNextGen Sciences Dx, Gainesville, FL, USA.
Simon LovestoneInstitute of Psychiatry, Department of Medicine and Neurosciences, King's College, London, UK.
Michelle M MielkeDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Sid O'BryantInternal Medicine Department, University of North Texas Health Sciences Center at Fort Worth, Fort Worth, TX, USA.
Manual SarasaAraclon Biotech, Zaragoza, Spain.
Magnus SjøgrenDiagenic ASA, Oslo, Norway.
Holly SoaresBristol Myers Squibb, Co., Wallingford, CT, USA.
Jessica TeelingUniversity of Southampton, Southampton, UK.
Eugenia TrushinaDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Malcolm WardProteome Sciences plc, London, UK.
Tim WestC2N Diagnostics, St Louis, MO, USA.
Lisa J BainIndependent Science Writer, Philadelphia, PA, USA.
Diana W ShinemanAlzheimer's Drug Discovery Foundation, New York, NY, USA.
Michael WeinerSchool of Medicine, University of California-San Francisco, San Francisco, CA, USA; Department of Veterans Affairs Medical Center, San Francisco, CA, USA.
Howard M FillitAlzheimer's Drug Discovery Foundation, New York, NY, USA.

Funding

Mitochondrial dynamics and metabolomic biomarkers in neurodegenerative disordersR01ES020715 · NIEHS · MAYO CLINIC ROCHESTER · PI TRUSHINA, EUGENIA · 2011 to 2015
$1.8M
Medical Research Council G0801464NIEHS NIH HHS R01 ES020715
6 · The paper itself

Abstract

Alzheimer's disease is the public health crisis of the 21st century. There is a clear need for a widely available, inexpensive and reliable method to diagnosis Alzheimer's disease in the earliest stages, track disease progression, and accelerate clinical development of new therapeutics. One avenue of research being explored is blood based biomarkers. In April 2012, the Alzheimer's Association and the Alzheimer's Drug Discovery Foundation convened top scientists from around the world to discuss the state of blood based biomarker development. This manuscript summarizes the meeting and the resultant discussion, including potential next steps to move this area of research forward.

Indexed as

Alzheimer DiseaseBiomarkersDisease ProgressionEarly DiagnosisEnzyme-Linked Immunosorbent AssayHumansBiomarkersAlzheimer's diseaseBiomarkerBlood based biomarkerDiagnosticsEarly detectionEarly diagnosis

Identifiers

PMID24365657
PMCPMC4769619

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.